C. Warren Olanow
#155,855
Most Influential Person Now
C. Warren Olanow's AcademicInfluence.com Rankings
C. Warren Olanowphilosophy Degrees
Philosophy
#8820
World Rank
#12276
Historical Rank
Logic
#5835
World Rank
#7276
Historical Rank
Download Badge
Philosophy
Why Is C. Warren Olanow Influential?
(Suggest an Edit or Addition)C. Warren Olanow's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. (2001) (1429)
- Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. (1993) (1186)
- Variable expression of Parkinson's disease (1990) (1167)
- Oxidative stress and the pathogenesis of Parkinson's disease (1996) (980)
- Transplantation of embryonic dopamine neurons for severe Parkinson's disease. (2001) (965)
- A radical hypothesis for neurodegeneration (1993) (749)
- Failure of the ubiquitin–proteasome system in Parkinson's disease (2001) (530)
- Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
- Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study (1992) (430)
- The pathogenesis of cell death in Parkinson's disease (2006) (414)
- Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
- An introduction to the free radical hypothesis in Parkinson's disease (1992) (381)
- Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. (1999) (356)
- Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa (1996) (356)
- DLB and PDD boundary issues (2007) (351)
- Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives (2014) (338)
- Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study (2010) (337)
- Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. (1989) (274)
- Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. (2004) (270)
- Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. (2000) (243)
- Manganese intoxication and chronic liver failure (1994) (229)
- Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. (1999) (228)
- Continuous dopamine-receptor stimulation in early Parkinson's disease (2000) (203)
- A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease (1994) (194)
- Oxidation reactions in Parkinson's disease (1990) (171)
- Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients (2013) (170)
- Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study (1994) (157)
- Oxidation reactions in Parkinson's disease. Discussion (1990) (150)
- Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. (1984) (147)
- The evolution and origin of motor complications in Parkinson's disease. (2000) (144)
- Preventing levodopa-induced dyskinesias. (2000) (132)
- Transgenic mouse model of early-onset DYT1 dystonia. (2005) (129)
- Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. (2004) (120)
- Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers (1993) (104)
- Stem cell treatment for Parkinson's disease: an update for 2005 (2005) (101)
- Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. (2000) (99)
- Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
- Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress (2003) (95)
- No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis (1981) (95)
- A Prospective Study of Thymectomy and Serum Acetylcholine Receptor Antibodies in Myasthenia Gravis (1982) (91)
- Iron induces degeneration of nigrostriatal neurons (1992) (90)
- Occupation and parkinsonism in three movement disorders clinics (2005) (90)
- Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. (2004) (89)
- Thymectomy as Primary Therapy in Myasthenia Gravis (1987) (86)
- Metals and free radicals in neurodegeneration. (1994) (80)
- Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease (1991) (77)
- Magnetic resonance imaging in parkinsonism. (1992) (76)
- Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra (1994) (76)
- Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? (1992) (76)
- Neurodegeneration and Neuroprotection in Parkinson's Disease (1996) (74)
- Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. (1990) (70)
- Four pioneers of L‐dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr (2015) (70)
- Neuroprotection for Parkinson's disease: Prospects and promises (2003) (69)
- Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease (2006) (69)
- Proteasomal dysfunction in sporadic Parkinson's disease (2006) (66)
- Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. (1995) (57)
- The core assessment program for intracerebral transplantation. (1995) (56)
- Parkinsonism and amiodarone therapy (1989) (53)
- Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
- A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data. (2000) (43)
- Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders (1996) (41)
- Thymectomy in late-onset myasthenia gravis. (1982) (41)
- Levodopa: why the controversy? (2002) (41)
- Iron and neurodegeneration (1996) (36)
- Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease. (1987) (35)
- Early morning off-medication dyskinesias, dystonia, and choreic subtypes. (2001) (34)
- Effect of thymectomy on peripheral lymphocyte subsets in myasthenia gravis: selective effect on T-cells in patients with thymic atrophy. (1983) (33)
- Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. (2000) (32)
- Speech therapy in Parkinson's disease (2002) (28)
- Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
- Adrenal medullary autografts in patients with Parkinson's disease. (1989) (28)
- Do subjects with minimal motor features have prodromal Parkinson disease? (2018) (27)
- Familial Benign Intracranial Hypertension and Depression (1982) (26)
- The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. (2000) (25)
- Valproic acid. Treatment of myoclonus in dyssynergia cerebellaris myoclonica. (1982) (21)
- Phenytoin: pharmacokinetics and clinical therapeutics. (1981) (20)
- Principles Of Treatment In Parkinson's Disease (2005) (20)
- Double-blind, placebo-controlled trials for surgical interventions in Parkinson disease. (2005) (20)
- Thymoma following transcervical thymectomy for myasthenia gravis. (1983) (19)
- Amantadine and other antiglutamate agents (2002) (19)
- The effect of L‐dopa infusions with and without phenylalanine challenges in parkinsonian patients (1993) (19)
- Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease (1991) (18)
- Neuroprotective Strategies in Parkinson’s Disease (2009) (17)
- Treatment of depression in idiopathic Parkinson's disease (2002) (17)
- Restorative Therapies in Parkinson's Disease (2006) (15)
- Pituitary adenoma presenting as facial pain: report of two cases and review of the literature. (1982) (15)
- An Open Multicenter Trial of Sinemet CR in Levodopa‐Naive Parkinson's Disease Patients (1991) (15)
- Brain Stem Glioma in Childhood: Acute Hemiplegic Onset (1981) (14)
- Drugs to treat dementia and psychosis (2002) (14)
- Transgenic mouse model of early-onset DYT 1 dystonia (2004) (13)
- MAO-B inhibitors in Parkinson's disease. (1993) (13)
- Autologous mixed lymphocyte reaction in patients with myasthenia gravis: correlation with disease activity. (1984) (13)
- The pathogenesis of myasthenia gravis--a hypothesis. (1981) (13)
- The effects of salicylate on the pharmacokinetics of phenytoin (1981) (13)
- MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
- Neonatal Myasthenia Gravis in the Infant of an Asymptomatic Thymectomized Mother (1982) (11)
- Parkinson's disease: Unresolved issues (2008) (11)
- Erratum: Neurogeneration and prospects for neuroprotection and rescue in Parkinson's disease (Annals of Neurology (53:S4)) (2003) (11)
- Selegiline HCl : selective MAO-type B inhibitor. Discussion (1990) (11)
- Intranigral iron infusion in rats: A progressive model for excess nigral iron levels in Parkinson’s disease? (1993) (11)
- Dyskinesias assessment workshop: reports from the working groups. (1999) (10)
- MR imaging of putamenal iron predicts response to dopaminergic therapy in parkinsonian patients (1990) (10)
- Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary. (1996) (10)
- Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. (1987) (10)
- Dyskinesias Associated with Lithium Therapy in Parkinsonism (1984) (10)
- Patients taking selegiline may have received more levodopa than necessary (1996) (10)
- RELATIONSHIP BETWEEN THE ACETYLCHOLINE RECEPTOR ANTIBODY TITER AND THE CLINICAL STATUS IN MYASTHENIA GRAVIS (1981) (9)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- Fetal grafts for Parkinson’s disease: Decades in the making (2016) (8)
- Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
- Free radicals and neurodegeneration. Author's reply (1994) (8)
- Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. (2000) (7)
- Movement disorders—a growing journal for a growing field (2014) (7)
- Psychosocial counseling in Parkinson's disease (2002) (6)
- "On-off" syndrome treated with lithium carbonate: a case report. (1981) (6)
- Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
- A double-blind controlled study of MK-486 in Parkinson's disease. (1973) (6)
- Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease (2005) (6)
- DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
- Intranigral Iron Infusion as a Model for Parkinson’s Disease (1994) (6)
- Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
- DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
- A scientific rationale for protective therapy in Parkinson's disease (2005) (6)
- The Neglected Side of Parkinson's Disease (2008) (5)
- Autologous adrenal medulla to caudate nucleus transplantation in advanced Parkinson's disease: 18 month results. (1990) (5)
- CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study. (1989) (5)
- Movement disorders: a step in the right direction (2006) (5)
- Chapter 6 – The Medical Management of Parkinson's Disease (2005) (5)
- Toward the use of surgical placebo-controlled trials. (1997) (5)
- Physical and occupational therapy in Parkinson's disease (2002) (5)
- Depression and benign intracranial hypertension. (1985) (4)
- DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
- Oxidative Stress in Parkinson's Disease (1997) (4)
- The effect of lithium on the "on-off" phenomenon in parkinsonism. (1983) (3)
- Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) (2005) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Early therapy for Parkinson's disease. (1991) (3)
- DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
- Continous dopamine-receptor stimulation in early Parkinson's disease (2000) (3)
- [Neurologic manifestations of hyperparathyroidism. Study of 120 cases]. (1982) (2)
- [Chorea in hyperparathyroidism. Report of a case]. (1981) (2)
- Thirty Second Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders (2019) (2)
- The Effect of Plasmapheresis on Post-Thymectomy Ocular Dysfunction (1981) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Levodopa-induced dyskinesias - Foreword (2000) (2)
- The role of comt inhibitors in the treatment of Parkinson's disease (2000) (2)
- Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
- Early therapy for Parkinson's disease. (1991) (2)
- Neurologic manifestations of hyperparathyroidism (1982) (2)
- Antiacetylcholine receptor antibody levels and MG (1982) (1)
- Prospects for neuroprotection in Parkinson’s disease (2006) (1)
- Advances in Research on Neurodegeneration (2000) (1)
- Preventing levodopa-induced dyskinesias. Discussion (2000) (1)
- On the mechanism of pathogenesis of human myasthenia gravis. (1981) (1)
- DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
- Advances in Research on Neurodegeneration (2000) (1)
- DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
- Melvin David Yahr, MD (1917–2004) (2004) (1)
- The early treatment of Parkinson's disease (1992) (1)
- Withdrawal of figure 2 from McNaught and Olanow's article, "Proteasome inhibitor-induced model of Parkinson's disease" (Ann Neurol 2006;60:243-247). (2009) (1)
- Anatomy and Functional Models of the Basal Ganglia (2001) (1)
- 2012 impact factor increases to 4.558 (2013) (1)
- DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
- Chapter 10 – Surgical Approaches to the Treatment of Parkinson's Disease (2005) (0)
- Call for Nominations (2004) (0)
- Disclosures to the special issue: The vatican conference on neuroprotection in Parkinson's disease volume 28, issue 1, january 2013 (2013) (0)
- EARLY THERAPY FOR PARKINSON'S DISEASE. AUTHORS' REPLY (1991) (0)
- Reply (1992) (0)
- A changing journal for a changing field (2010) (0)
- DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
- Deep-brain stimulation in Parkinson's disease [2] (multiple letters) (2002) (0)
- Initiating Therapy in Parkinson's Disease Reply (2009) (0)
- DA agonists ‐ Overview (2002) (0)
- Reply (1996) (0)
- New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
- Reply (2009) (0)
- AChR antibody titer and clinical response to thymectomy in MG (1984) (0)
- Impact factor for 2013 (2014) (0)
- Patients taking selegiline may have received more levodopa than necessary (1996) (0)
- Initiating Therapy in Parkinson's Disease. Authors' reply (2009) (0)
- Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always (2019) (0)
- Reply (1996) (0)
- Current concepts in the management of movement disorders. (1981) (0)
- Oliver Wolf Sacks, BMBCh, FRCP, CBE (1933–2015) (2016) (0)
- The effect of salicylate on phenytoin pharmacokinetics. (1979) (0)
- MRI (2017) (0)
- Textbook of Neural Repair and Rehabilitation: Cell transplantation therapy for Parkinson's disease (2006) (0)
- Reply to: “A New Approach to the Development of Disease‐Modifying Therapies for PD” (2021) (0)
- Reply (1994) (0)
- Reply (1983) (0)
- Reply (1997) (0)
- Call for nominations (2005) (0)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- Reply (1999) (0)
- Call for nominations (2004) (0)
- Inflammatory Response and Oxidate Stress in the Degeneration of Dopamine Neurons in Parkinson's Disease (2003) (0)
- The Neglected Side of Parkinson's Disease Shaking and slowness of movement may be the most obvious symptoms, (2016) (0)
- Parkinson's disease slide library (1996) (0)
- A new approach to late onset myasthenia gravis. (1985) (0)
- Call for nominations: Deadline for editor nomination: March 15, 2005 (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With C. Warren Olanow?
C. Warren Olanow is affiliated with the following schools:
